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Protein fiber formation is associated with diseases
ranging from Alzheimer’s to type II diabetes. For
many systems, including islet amyloid polypeptide
(IAPP) from type II diabetes, fibrillogenesis can be
catalyzed by lipid bilayers. Paradoxically, amyloid
fibers are b sheet rich while membrane-stabilized
states are a-helical. Here, a small molecule a helix
mimetic, IS5, is shown to inhibit bilayer catalysis of
fibrillogenesis and to rescue IAPP-induced toxicity
in cell culture. Importantly, IAPP:IS5 interactions
localize to the putative a-helical region of IAPP,
revealing that a-helical states are on pathway to fiber
formation. IAPP is not normally amyloidogenic as its
cosecreted partner, insulin, prevents self-assembly.
Here, we show that IS5 inhibition is synergistic with
insulin. IS5 therefore represents a new approach to
amyloid inhibition as the target is an assembly inter-
mediate thatmay additionally restore functional IAPP
expression.
INTRODUCTION
Type II diabetes is an increasingly prevalent disease character-
ized by the loss of blood glucose homeostasis and systemic
insulin resistance. The consequences of diabetes are far reach-
ing, resulting in greatly increased risks of heart disease, kidney
damage, and circulatory problems. The current epidemic of
obesity in the United States and Europe is expected to increase
the prevalence of diabetes in children as well as adults (Pontiroli,
2004). It is therefore of great importance to understand the
causes and factors implicated in diabetic pathology. One unique
feature of the pathology is the formation of proteinaceous pla-
ques in the endocrine pancreas (Haataja et al., 2008; Hoppener
et al., 2000; Kahn et al., 1999). These amyloid plaques are
composed primarily of fibers formed from islet amyloid polypep-
tide (IAPP). Fiber formation is a widespread phenomenon in
a number of other important diseases such as Alzheimer’s in
which the Ab peptide aggregates to form amyloid plaques
(Finder and Glockshuber, 2007).
The misfolding and self-assembly of IAPP into fibers is corre-
lated with the loss of insulin secreting b cells. IAPP is a 37 amino
acid, natively unstructured peptide hormone that is copackagedChemistry & Biology 16, 943–with insulin in the secretory granules of the b cells (Clark and
Nilsson, 2004; Hull et al., 2004). In addition, insulin and IAPP
demonstrate coregulated expression and are coprocessed by
a common convertase (Badman et al., 1996). As a hormone,
many activities have been attributed to IAPP, ranging from regu-
lation of gastric emptying to paracrine/autocrine feedback
(Cooper, 1994; Hay et al., 2004). The latter is evident in the fact
that transgenic human IAPP (hIAPP) rats have defective insulin
secretion profiles (Matveyenko and Butler, 2006a). In addition,
insulin likely plays an important role in preventing IAPP aggrega-
tion in vivo, as insulin is a potent inhibitor of IAPP aggregation
in vitro (Larson and Miranker, 2004). The link between IAPP
amyloid and disease states (Porte and Kahn, 2001; Marzban
et al., 2003) has been supported recently by transgenic rat
models for type II diabetes (Matveyenko and Butler, 2006b).
Rat IAPP (rIAPP) does not readily aggregate in vitro and rats
do not spontaneously develop type II diabetes. In contrast,
rodents transgenic for hIAPP develop symptoms similar to type
II diabetes. A notable example among these is the HIP rat, which
closely follows the human progression of diabetes, including
systemic insulin resistance, elevated glucose levels, and loss
of b cell mass (Matveyenko and Butler, 2006a). These findings
have clearly linked IAPP misfolding to b cell death and increased
pathogenicity in type II diabetes.
Amyloid proteins misfold and aggregate into highly ordered
fibrous structures. These are characterized by the noncovalent
assembly of b strands. These strands form sets of two or more
b sheets that run the entire length of a fiber (Tycko, 2006).
Such states are highly stable, often demonstrating strong resis-
tance to chemical and proteolytic degradation. The assembly
pathway of amyloid is that of a nucleation-dependent polymeri-
zation (Frieden, 2007; Powers and Powers, 2008; Ruschak and
Miranker, 2007). Nucleation-dependent polymerization is char-
acterized by kinetic profiles beginning with a lag phase, where
no detectable fiber is generated. Nucleation represents the initial
formation of states that are competent to elongate. This results in
an apparently cooperative kinetic transition to the final amyloid
state. Such systems effectively behave like 1D crystals with
the nucleation processes bypassable by seeding with the addi-
tion of preformed fibers (Harper and Lansbury, 1997).
The crystal-like propagation properties of fibers have been
widely capitalized on to identify inhibitors based on crystal
poisoning. In this approach, inhibitors are designed to possess
sufficient structure to bind fiber ends. Once bound, further addi-
tion of precursor is prohibited. Early examples of this for Alz-
heimer’s disease include modified variants of a subpeptide,950, September 25, 2009 ª2009 Elsevier Ltd All rights reserved 943
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include not only subpeptides but also full-length IAPP in which
the backbone amide has been methylated (Yan et al., 2006)
and nonamyloidogenic point mutations (Abedini et al., 2007).
An alternative approach has been to identify small molecules
that interfere with assembly. For example, a lead compound,
DAPH, has been shown to inhibit Ab amyloid aggregation and
toxicity (Wang et al., 2008). Like DAPH, many of these
compounds are polycyclic (Aitken et al., 2003; LeVine, 2007) or
polyphenolic (Porat et al., 2006; Bastianetto et al., 2008). It has
been proposed that the majority of these compounds act by
intercalating between b strands or b sheets, disrupting interme-
diate and fiber state interactions (Porat et al., 2004, 2006).
Recently, several polycyclic compounds that bind a-synuclein
have been shown by nuclear magnetic resonance (NMR) to
bind to the same subset of residues, further suggesting
a common molecular basis for their inhibition of amyloid forma-
tion (Rao et al., 2008).
The fiber state represents the product of amyloidogenesis;
however, it is the intermediates of amyloid formation that repre-
sent the toxic species (Lashuel and Lansbury, 2006; Hebda and
Miranker, 2009). This has long been conjectured as a result of the
poor correlation between amyloid burden and disease pathology
such as dementia in Alzheimer’s. The current paradigm is that
toxicity is mediated by intermediate oligomeric states that act
by permeabilizing lipid bilayers. Oligomers bound to cellular
membranes have been visualized using oligomer-specific anti-
bodies in a number of amyloid systems (Gong et al., 2003; Kayed
et al., 2004). In our own work, we determined that IAPP can bind
to lipid bilayers to form monodisperse and heterogeneous oligo-
meric populations (Knight et al., 2006). Remarkably, both states
are predominantly a-helical with the latter having a high capacity
to render model membranes permeable to cations and small
molecules. These oligomeric states were also best correlated
to efficient catalysis of fiber formation. The a-helical region of
IAPP has been mapped to an 20 residue subdomain (see
Figures 1B and 1C). When synthesized as a separate peptide,
IAPP1-19 can bind to membranes and adopt an a-helical,
membrane-permeabilizing state, but does not progress to
form amyloid (Brender et al., 2008). We hypothesize that mem-
brane-bound a-helical oligomers represent the toxic species
and are on pathway to amyloid formation. Toward that end, we
have screened amyloid inhibitors that have been rationally
designed to interact with a-helical states. This design strategy
(Saraogi and Hamilton, 2008) has here enabled a kinetic and
structural elucidation of the role of a-helical states in affecting
the IAPP disorder to amyloid transition.
RESULTS
In this work, a synthetic, a-helical protein mimetic scaffold is
used to probe IAPP fiber formation. The IS scaffold is particularly
relevant to IAPP and possibly other amyloid peptides (such as
Ab42 and a-synuclein) as these systems sample a-helical states
as part of the amyloid formation process (Hebda and Miranker,
2009). The IS scaffold is organized so as to facially project func-
tional groups at i, i + 3 (or i + 4), i + 7. spacings. A number of
compounds have recently been assayed for their effects on
IAPP fiber formation (Saraogi et al., 2009). Here, we have944 Chemistry & Biology 16, 943–950, September 25, 2009 ª2009selected a pentameric IS compound that presents five carboxyl-
ates, IS5 (Figure 1A), for detailed study. Specifically, we study
the effect of IS5 on the kinetics of fiber formation in solution,
as catalyzed by lipid bilayer surfaces, in seeded elongation
assays and in ternary reactions with a cosecreted hormone,
insulin. Kinetic effects are compared to structural measurements
using 1D and 2D NMR. Our goal is to probe the mechanism of
amyloid fiber assembly and to relate mechanistic information
to possible pharmacological strategies.
Nucleation of IAPP fiber formation is accelerated by addition of
IS5. Fiber formation reactions were conducted in 96 well plates
using the fluorescence of thioflavin T (ThT) as an indicator of
amyloid assembly. Briefly, reactions are initiated by dilution of
a DMSO stock of IAPP into buffer (pH 7.4; 50 mM phosphate
and 100 mM KCl) at 25C. Fiber formation was monitored using
the time-dependent change in the fluorescence intensity of ThT
(LeVine, 2007). IAPP gives nucleation-dependent kinetic profiles
characterized, in part, by sigmoidal shape (Figure 2). Kinetic
rates are characterized from these profiles using the reaction
midpoint, or t50. Due to effects of IS5 interfering with ThT inten-
sity, the t50 and not absolute intensity was used as an indicator
of IS5’s effects on fiber formation reactions. The t50 were
obtained by fitting the kinetic traces to a sigmoid (see Equation 1
in the Supplemental Experimental Procedures available online),
with the inflection point of the curve taken as representing the
reaction t50.
Amyloid formation by IAPP in solution is accelerated by IS5
primarily as a result of changes to the rate of primary nucleation.
This is suggested, in part, by the dramatic decrease in fiber
formation lag time in the presence of IS5 (Figure 2A). Conduction
of a 10 mM IAPP fiber formation reaction in the presence of 10 mM
IS5 under standard solution conditions results in a t50 that is
0.18 ± 0.02 times as long as a control reaction in the absence
of IS5 (3.6 ± 0.3 hr and 20.1 ± 0.6 hr, respectively). Intriguingly,
the magnitude of this effect is still large (0.63 ± 0.03) even at
1 mM IS5 (data not shown). One possible origin for this effect is
that IS5 acts on intermediates that form on the 3–4 hr time scale.
In repeat experiments in which IS5 is instead added after 4 hr to
an IS5-free reaction, a t50 of 8.1 ± 0.3 hr is observed (data not
shown). In this case, the fiber formation reaction is occurring
4 hr after contact with IS5. We conclude that IS5 does not
act on late (3–4 hr) intermediate species. Rather, interactions
occur with very early species and/or a monomeric precursor.
That IS5 potently accelerates fiber formation is of mechanistic
interest as the complex it forms appears to promote the initial
nucleation of fibers.
This is further supported by the absence of an IS5 effect on
seeded reaction kinetics. Seeded kinetics are collected by
providing amyloid reactions with preformed fibers. Reaction
profiles are typically exponential, as seeded fiber formation is
driven predominantly by elongation. The presence of sigmoidal
behavior in such reactions is a consequence of contributions
from secondary nucleation processes, i.e., the fiber-dependent
production of new fiber ends, such as might occur as a result
of fiber breakage. Here, the t50 of a 20 mM IAPP reaction con-
ducted in the presence of 4 mM of preformed fiber seed is
2.3 ± 0.2 hr (Figure 2B). The profile retains sigmoidal character
and as the t50 is substantially less than the unseeded reaction
t50, this indicates the presence of both elongation and secondaryElsevier Ltd All rights reserved
Figure 1. Structural Representations of IS5 and IAPP
(A) Structure of the helix mimetic compound IS5.
(B) Alignment of human and rat sequences of IAPP. Helical states sampled by both hIAPP and rIAPP in dilute solution and on membranes are indicated with a
cylinder (Williamson andMiranker, 2007). b strands that were unambiguously determined by solid state NMRof hIAPP fibers are indicated with arrows (Luca et al.,
2007).
(C) Helical wheel representation of residues 1–21. Polar residues are shown in white, charged in blue, and aliphatics in green. A disulfide between residues 2 and 7
is indicated with a dashed line.
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andMiranker, 2002). Importantly, the addition of 20 mM IS5 to an
otherwise identical reaction yields only mild inhibition, t50 = 2.8 ±
0.1 hr. Acceleration of solution phase reactions, but not seeded
reactions, clearly shows that IS5 affects primary nucleation
events. Neither elongation nor secondary nucleation processes
represent targets of IS5.
IS5 acts as an inhibitor of lipid bilayer-catalyzed fiber forma-
tion. IAPP fiber formation is readily accelerated by lipid bilayers
in a process associated with disease pathology (Hebda and
Miranker, 2009). Here, we use a 1:1 mixture of 1,2-dioleoyl-sn-
glycero-3-phosphocholine (DOPC) and 1,2-dioleoyl-sn-glycero-
3-phospho-(10-rac-gylcerol) (DOPG) lipids, extruded into 100 nm
unilamellar vesicles as a reagent. At 10 mM IAPP and 630 mM
lipid, the amyloid reaction t50 is 0.63 ± 0.01 hr (Figure 2C). Addi-
tion of IS5 at 10 mM to the former reaction conditions clearly
results in inhibition giving a t50 of 2.1 ± 0.1 hr (Figure 2C). Like
any ligand, the potency of IS5 will be affected by the structure
and energetic details of its interaction with IAPP. At a molecular
level, we note that IS5 is a polyanion with a calculated logP of
6.9 and is therefore unlikely to partition into a lipid bilayer.
A compound with similar anionic character, diethylene triamine
pentaacetic acid, showed no effects on lipid-catalyzed IAPP
fiber formation (Saraogi et al., 2009). This suggests that IAPP:IS5
interactions have molecular specificity.Chemistry & Biology 16, 943–IS5 inhibits hIAPP-induced cytotoxicity. The effect of hIAPP
on INS-1 cells, a well-characterized b cell model (Hohmeier
et al., 2000), was assessed by the 3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) cell viability assay.
hIAPP exhibited strong cytotoxic effects, with cell viability de-
creased to 50% in the presence of 5 mM hIAPP and 40% in
the presence of 10 mM hIAPP (Figure 2D). IS5 significantly
reduced the toxic effects of hIAPP, with complete rescue (i.e.,
100% cell viability) observed at an IS5 to peptide ratio of 2:1.
IS5 exhibited no intrinsic cytotoxicity up to 50 mM (data not
shown). Melittin, from bee venom, was used as a positive control
as its cytotoxicity is associated with a disordered to a-helix
transition upon binding lipid bilayers. At 5 mM, melittin reduced
cell viability by 98% and was not rescued even at ratios of
5:1 (IS5/melittin) (data not shown). This suggests that the
amelioration of toxicity by IS5 is specific for structures formed
by IAPP.
Solution phase interactions of IAPP with IS5 were determined
by heteronuclear NMR. NMR spectra were collected using the
sequence variant of IAPP from rats (rIAPP). rIAPP binds lipid bila-
yers with comparable properties to hIAPP, can disrupt mem-
brane integrity, and yet does not readily form aggregates (Knight
et al., 2006). IS5 was titrated from 0 to 475 mM into a sample con-
taining 120 mM rIAPP at pH 6.5 and monitored by 1H 15N HSQC
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Figure 2. Effect of IS5 on the Kinetics of
hIAPP Fiber Formation
Representative traces showing the effect of IS5 on
de novo fiber formation in solution (A), on solution
phase fiber formation seeded with preformed
fibers (B), on de novo fiber formation catalyzed
by a lipid bilayer (C), and on IAPP-induced cell
toxicity (D).
(A–C) Reactions were performed in the presence
(filled) and absence (open) of compound (1:1 IS5/
IAPP). De novo reactions contained 10 mM hIAPP
and 10 mM IS5. Seeded kinetics were performed
at 20 mM hIAPP with the addition of 4 mM pre-
formed IAPP fibers and 20 mM IS5. Lipid catalysis
was performed by addition of 630 mM lipid in the
form of a 1:1 mixture of DOPG/DOPC unilamellar
liposomes.
(D) Inhibition of hIAPP cell toxicity by IS5. INS-1
cells were treated with hIAPP (5 mM [gray] or
10 mM [black]) and the indicated concentration of
IS5. Cell viability was then assayed by MTT reduc-
tion (see Supplemental Experimental Procedures).
Results are expressed as percentages of the
control cells exposed only to a matched volume
of neat DMSO. All experiments performed at least
in triplicate. For (D), error bars represent SEM. For
(A)–(C), statistics are quoted in the main text.balance issues of solubility of IS5 and tominimize signal loss due
to amide hydrogen exchange. The acceleration of hIAPP fiber
formation by IS5 reported here at pH 7.4 is unaffected by this
drop in pH (data not shown).
IS5 causes shifts of amide peaks within the helical domain of
IAPP. Shifts were observed for all residues spanning 5 to 19.
This region has previously been characterized by NMR as intrin-
sically disordered with a strong bias toward the sampling of
a-helical states (Williamson and Miranker, 2007). No significant
shifts were observed for residues 23–37 (Figure 3B). For
example, serine 19 and 20 shift dramatically, whereas serine
34 is unaffected (Figure 3A). This trend of unchanged
(C-terminal residues) versus shifted peaks (N-terminal residues)
can clearly be noted between 0 mM and 475 mM IS5 (Figure 3B).
Importantly, binding is nearing saturation at the highest concen-
trations of IS5 used (Figure S2). These binding data fit well to
a single binding event (R2 > 0.97) with an apparent binding
affinity of 160 ± 20 mM. No shifts are apparent in control titra-
tions using only DMSO (data not shown). The localization of
perturbation to residues 5–19 of IAPP clearly implicates this
region as the site of action of IS5. For hIAPP, it is possible
that additional shifts could occur beyond residue 19, but these
are prevented by the three proline residues present only in
rIAPP. Thus, while it remains possible that the extent of IS5
interactions with hIAPP is greater than that observed in rIAPP,
it is nevertheless clear that the helical region of IAPP is important
to primary nucleation.
IS5 reduces the extent of IAPP binding to lipid bilayers.
Binding of IAPP to liposomes can be measured with limited
residue specificity using liposomes composed of 1:1 DOPG/
DOPC and 1H NMR (Figure 3C). Titrating rIAPP (with and without
IS5) with increasing concentrations of liposomes clearly shows
a diminishment of several peaks assignable to the helical region.
Here, we highlight the aryl proton peaks of residue 15. In the946 Chemistry & Biology 16, 943–950, September 25, 2009 ª2009absence of liposomes, the addition of IS5 to IAPP causes
marked shifts to the aryl peaks of F15 (Figure 3C). In the absence
of IS5, the peaks of F15 can readily be seen to broaden and lose
intensity upon titration with liposomes (Figure 3C and Figure S3).
Importantly, the extent of this signal loss is greatly diminished
when equimolar IS5 is present. This observation can similarly
be made directly as IS5 reduces the extent of cofloatation of
rIAPP with liposomes upon centrifugation (Figure S3D). This
suggests that IS5 is competing with the lipid surface for IAPP
binding, thereby lowering the effective binding affinity of IAPP
for the lipid surface.
The capacity of IS5 to act as inhibitor of lipid-catalyzed fiber
formation is increased in the presence of insulin (Figure 4). We
previously showed that insulin is a remarkably potent inhibitor
of solution phase fiber formation (Larson and Miranker, 2004).
Substoichiometric insulin readily inhibits solution phase IAPP
fiber formation by greater than 10-fold. In marked contrast, we
have recently shown that insulin is a weak inhibitor of lipid
bilayer-catalyzed fiber formation (Knight et al., 2008). This obser-
vation led us to speculate that changes in lipid biochemistry
might serve as a trigger for amyloid formation in type II diabetes
(Knight and Miranker, 2004). What we characterize as weak
inhibition by insulin is shown here in the context of the lipid catal-
ysis of a 10 mM IAPP reaction (Figure 4). Addition of 5-fold molar
excess of insulin to such a reaction results in a t50 that is 6.0 ± 0.4
times slower than the parent reaction. Importantly, whereas in
the absence of insulin, 10 mM IS5 inhibits the lipid-catalyzed t50
by 2.3 ± 0.2-fold, in the presence of 50 mM insulin, 10 mM IS5
results in a t50 delayed by 15 ± 1.7-fold. This dramatic increase
in inhibition is consistent with a model where pre-amyloidogenic
forms of IAPP bound to lipid membranes are protected from
insulin inhibition (Knight et al., 2008). Here, it appears that IS5
is able to compete IAPP off the lipid surface, increasing the
accessibility of insulin to IAPP.Elsevier Ltd All rights reserved
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Oligopyridylamides represent a novel class of amyloid fiber
formation effectors. Here, this class of compounds gives struc-
turally specific insight into the processes of IAPP amyloid
assembly. IS5 specifically inhibits fiber formation under lipid
bilayer-catalyzed conditions. The in vivo potential for this
approach is shown by IS5’s ability to rescue IAPP-induced cyto-
toxicity. We show that this helix mimetic indeed binds to the
helical region of IAPP. In the absence of a bilayer, stabilization
of the helical region presumably results in structural rearrange-
ments that accelerate aqueous phase nucleation. In the ER
and/or granule lumen in vivo, IAPP is expressed in close prox-
imity to insulin. Here, we have shown that IS5 can act synergis-
tically with insulin to inhibit lipid-catalyzed fibrillogenesis.
The helical region of IAPP catalyzes amyloid nucleation. IS5
binds directly to the helical region of IAPP and accelerates de
novo, solution phase fiber formation. Helical states of IAPP
have been suggested to be important for kinetics both on lipo-
somes and in solution. In the fiber state, IAPP forms in-register
parallel b sheets (i.e., residue i of strand j stacks on top of residue
i of strand j + 1). This structural characteristic explains the insen-
sitivity to primary sequence in some amyloid fibers. For example,























































Figure 3. Structural Characterizations of IS5:IAPP Interactions
(A) Overlay of 1H-15N HSQC spectra of rIAPP showing shifts upon titration with
IS5. A representative region of the full spectrum is shown with the indicated
concentrations of IS5.
(B) Per residue D ppm between 0 and 475 mM IS5 showing the peak shifts
within the helical region. Contributions from proton and nitrogen dimensions
were combined and scaled as per Grzesiek et al. (1996). Peaks were not
detected (ND) for residues 1–3, and prolines at residues 25, 28, and 29 result
in no peaks (Pro). Residues 24, 26, and 27 have two assigned peaks (William-
son and Miranker, 2007), with each shown as separate values.
(C) Effect of IS5 on rIAPP lipid binding assessed by 1H NMR signal loss of
phenylalanine 15 (F15). Spectra of 150 mM rIAPP in the presence or absence
of liposomes (1.25mM lipid at 1:1 DOPG/DOPC) or in the presence or absence
of 150 mM IS5 are indicated on right. Aryl protons of F15 in 1D 1H spectra are
indicated using a gray background. IS5 alone (middle spectrum) is shown to
confirm that these effects are not due to signal overlap with the F15 peaks.Chemistry & Biology 16, 943–9sequence is scrambled (Ross et al., 2004). In marked contrast,
IAPP shows exquisite sensitivity to sequence order within
its helical subdomain. The double mutants L12N/N14L and
N14L/L16N have previously been shown to dramatically atten-
uate amyloid formation (Koo et al., 2008). Our data therefore
support a model whereby the N-terminal helical region promotes
formation of early intermediate states that allow b sheet forma-
tion to be initiated by some subset of the residues 20–37. This
b sheet intermediate would then convert to the strand-loop-
strand structure similar to the solid state NMR structure
proposed by Luca et al. (2007) (Figure 1C). Inhibition by IS5
supports the direct assignment of helix-mediated nucleation as
an element of the mechanism of IAPP fiber formation.
The presence of helix-based intermediates and the use of oli-
gopyridylamide scaffolds holds the promise of creating highly
specific attenuators of amyloid toxicity. Previous small molecule
studies have relied on disruption of intermolecular contacts
between b sheets. This mode of action explains the common
ability for these classes of inhibitors to work in various amyloid
systems (Porat et al., 2006). Other approaches take advantage
of the 1D crystalline nature of amyloid fibers, using modified
forms of the protein to disrupt amyloid formation. Such
approaches are highly specific, but target fiber formation itself.
The absence of any effect on elongation by IS5 indicates that it
does not affect propagation of the amyloid structure
(Figure 2B). It is therefore likely that N-terminal helix formation
is not a feature of elongation. Plainly, IS5 is mechanistically
distinct from the b sheet breaker or crystal poison class of
small molecule inhibitors. Recent work has shown that
libraries of thousands of helix mimetic compounds can be
synthesized (Shaginian et al., 2009). This is afforded by the




















Figure 4. Synergy of Inhibition by IS5 and Insulin
Representative traces of IAPP amyloid formation kinetics conducted under
lipid-catalyzed conditions (630 mM lipid at 1:1 DOPG/DOPC). Control lipid-
catalyzed IAPP kinetics at 10 mM IAPP (triangles) are inhibited by addition of
10 mM IS5 (diamonds) or 50 mM insulin (circles). Simultaneous addition
of both 10 mM IS5 and 50 mM insulin dramatically increases the inhibition of
lipid-catalyzed kinetics (squares). Fits of the data to sigmoidal transitions are
shown. Confidence intervals from triplicates are expressed in the text.50, September 25, 2009 ª2009 Elsevier Ltd All rights reserved 947
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promising drug candidates.
Inhibition by IS5 may further represent a type II diabetes-
specific approach to compensate for loss of proteostasis control
of IAPP by insulin. Proteostasis processes balance protein
expression, localization, and degradation by enhancing folding
and preventing misfolding through proper maintenance of chap-
erone levels. Restoring occurrences where this balance is lost
would greatly aid the treatment of many diseases (Balch et al.,
2008). Small molecules have been used to target improvements
in homeostasis by two major avenues. First, target proteins can
be stabilized by ligand binding, preventingmisfolding and degra-
dation. For example, the p53 mutant I195T can be stabilized by
the peptide CDB3, which effectively acts as a synthetic chap-
erone (Friedler et al., 2002). Alternatively, celastrol and MG-132
have been used to upregulate core proteostasis machinery
such as Hsp40 and Hsp70 (Mu et al., 2008). Upregulation of
these core proteostasis proteins improves cell response to mis-
folding stress (Balch et al., 2008). These efforts show the impor-
tance of treating proteostasis machinery as a target for thera-
peutic intervention. Although insulin is not part of the unfolded
protein response, it is cosecreted and coregulated with IAPP
and is able to inhibit its fiber formation. Interestingly, insulin is
a poor inhibitor of lipid-catalyzed IAPP fiber formation (Knight
et al., 2008). We surmise that fiber formation in diabetes is an
issue of localization. Lipid-bound IAPP is accessible to insulin
(Knight et al., 2008) but does not form a structure with insulin
that can effectively inhibit amyloidogenesis. Addition of IS5
partially rescues this effect and acts additively with insulin to
inhibit amyloid formation. This restoration of native insulin inhibi-
tion may therefore represent a disease-specific opportunity to
restore protein homeostasis and therefore prevent IAPP aggre-
gation in type II diabetes.
SIGNIFICANCE
The oligopyridylamide IS5 interferes with lipid bilayer-bound
states by targeting helical forms of IAPP. Our results clearly
support the hypothesis that a-helical states are on pathway
to b sheet fiber formation. More broadly, helical structure
stabilized by lipid bilayers has been implicated in the mech-
anisms of other amyloid diseases including Ab from
Alzheimer’s and a-synuclein from Parkinson’s (Hebda and
Miranker, 2009). For all three systems, there is interplay
between structure formation, catalysis of fibrillogenesis,
and cytotoxic loss of membrane integrity. In a-synuclein
two helical states have been identified: one that is extended
(Eliezer et al., 2001) and a second in which two helices are
separated by a kink (Chandra et al., 2003). These alternative
forms are suggested to have functional and/or pathological
significance with respect to a-synuclein’s ability to bind
curved anionic vesicles. There are many suggested mecha-
nisms for the origins of membrane integrity loss induced by
these helical states. For example, Ab can bindmembranes in
both lateral and transverse orientations (Bokvist et al., 2004;
Chi et al., 2008). Subpeptide analyses have shown that IAPP
helical statesmay behave similarly (Brender et al., 2008). It is
therefore plausible that modulation between the two modes948 Chemistry & Biology 16, 943–950, September 25, 2009 ª2009facilitates the depolarization of gradients across cellular
membranes (Huang et al., 2004). Other suggested mecha-
nisms include behavior that is detergent- and carpet-like
and the direct formation of pores (Lashuel and Lansbury,
2006). This apparent range of possibility reveals the relative
paucity of molecular level understanding. Specific targeting
of helical, membrane-associated states using peptidomi-
metics will therefore enable the probing of these mecha-
nisms through structure-activity relationships. This will
further refine our ability to usemimetic compounds to target
intermediates of amyloid rather than the fibers themselves.
As IS5 rescues a-helical intermediate-induced cytotoxicity,
such targeting represents a rich and novel area for the
successful production of therapeutics.
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